Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region
about
Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected]Synthesis, encapsulation and antitumor activity of new betulin derivatives.High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41HIV entry inhibitors and their potential in HIV therapyNew anti-HIV agents and targets.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agentsEscape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.Genetically intact but functionally impaired HIV-1 Env glycoproteins in the T-cell reservoir.
P2860
Q28345233-88033BC6-04C3-4628-B32B-057EBBF768C2Q28485218-D4AB5DC3-1557-46C4-8E2C-39F56AA86824Q30318499-C4CA5D49-56AF-4F87-9E43-1D54A356555FQ30846393-9416DFBD-D690-4AA2-BAE6-F1C0FF459899Q33966639-B76555A8-C727-41BE-A295-CDEDC3CE5992Q34595921-7919710B-843B-4549-8D47-B1BACAB4BF7FQ34944447-D8D29259-F7C2-4CBF-A810-869E781EECD2Q35917148-4305D622-1733-45BD-B82F-2708F6F8BB5BQ36187060-F0DE998C-CD30-4CD9-BDA0-6B68DC72382CQ37330178-1331F2CD-7022-4084-BC73-14BAE445AA27Q38076139-0CA77459-7ED3-4D29-A43B-AE03335013F0Q39602915-5D6AF7C4-F986-4B0D-B62C-BD65F9F690E5Q39612212-E7C23B1C-F743-404D-BFA3-6188AB879D69Q40063752-34E22AD6-8C54-46B9-93C7-FA576E875A8DQ40604377-D7FB97E0-1E9D-4CBF-A569-EF1E3A4F0CFBQ47350110-561BB3CE-92B5-44B9-A6C0-CC5224F351A4
P2860
Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@ast
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@en
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@nl
type
label
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@ast
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@en
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@nl
prefLabel
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@ast
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@en
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@nl
P2093
P2860
P1433
P1476
Sensitivity to a nonpeptidic c ...... bility of the gp41 loop region
@en
P2093
P2860
P304
P356
10.1128/JVI.74.5.2142-2150.2000
P407
P577
2000-03-01T00:00:00Z